Previous Article | Next Article 
Infection and Immunity, February 2001, p. 1072-1083, Vol. 69, No. 2
Dipartimento di Biologia Cellulare e dello Sviluppo,
Sezione di Scienze Microbiologiche, and Istituto Pasteur Fondazione
Cenci Bolognetti, Università `La Sapienza,' 00185 Rome,
Italy1; Unité de Pathogénie
Microbienne Moléculaire, Institut Pasteur, Paris,
France2; and Laboratoire de
Bactériologie Expérimentale, Institut Pasteur de Dakar,
Dakar, Senegal3
Received 5 July 2000/Returned for modification 31 August
2000/Accepted 25 October 2000
Because the use of live attenuated mutants of Shigella
spp. represents a promising approach to protection against bacillary dysentery (M. E. Etherridge, A. T. M. Shamsul Hoque, and
D. A. Sack, Lab. Anim. Sci. 46:61-66, 1996), it becomes
essential to rationalize this approach in animal models in order to
optimize attenuation of virulence in the vaccine candidates, as well as their route and mode of administration, and to define the correlates of
protection. In this study, we have compared three strains of Shigella flexneri 5 Shigella flexneri is the
major etiological agent of endemic bacillary dysentery, a severe form
of diarrhea responsible for approximately 1 million fatalities annually
(20). The disease is characterized by bacterial invasion
of colonic epithelial cells, leading to an intense inflammatory
response with severe destruction of the colonic mucosa
(22). The invasion process requires the concerted action
of specific virulence factors encoded by a plasmid (41,
45) and chromosomally encoded metabolic functions necessary for
the bacteria to survive within the host (3, 34). In
ligated intestinal loops of rabbits, early entry of S. flexneri occurs via M cells of the follicle-associated epithelium
of Peyer's patches (PPs) (51, 44). Similarly, after
intragastric (i.g.) inoculation of macaques, S. flexneri
uses lymphoid structures associated with the colonic and rectal mucosae
as its primary site of entry (43). Once the lymphoid
structures have been reached, bacteria encounter resident macrophages
that are rapidly killed by apoptosis, due to the ability of IpaB, a
62-kDa bacterial invasin, to activate caspase 1 (14, 55,
56). The death of the macrophages may facilitate bacterial
survival in these tissues, but it causes a substantial release of
interleukin-1 Our current understanding of Shigella infection mechanisms
is at a stage in which identification and characterization of the major
factors of the invasion process must be integrated into a scheme that
can be established only by using in vivo models of infection. This
integration is essential for design and improvement of live attenuated
vaccine candidates. However, in vivo studies are complicated by the
relatively innate resistance of most animals to oral infection by
S. flexneri (24), which impairs the coordinated analysis of invasion, inflammation, and immunity. In studies aimed at
exploring protection against shigellosis, Shigella vaccines are often evaluated using methods of inoculation that differ from the
normal route of infection (11). A murine model based on intranasal (i.n.) infection has been developed and used in various protection experiments (25). Virulent shigellae invade
murine bronchial and alveolar epithelia, where they elicit both acute suppurative infiltrates and epithelial necrosis (26, 49). Mice immunized with wild-type S. flexneri strains or
attenuated vaccine strains exhibit partial protective immunity to
subsequent i.n. challenges with a lethal Shigella inoculum
(37). The ability of Shigella spp. to invade
the corneal epithelium of guinea pigs, rabbits, and mice, spread to
contiguous cells, and cause keratoconjunctivitis (i.e., the Sereny test
[46]) has also become a major model system. This model
has been used to test potential vaccine candidates for attenuation
(12, 13, 47) and to evaluate vaccine efficacy (11,
15, 30, 32). Nevertheless, the oral route has also been used to
administer Shigella strains and vaccine candidates to
various animals (18, 24, 31, 54) to stimulate local protective immunity that reflects the natural route of infection. Despite this variety of approaches, the response of the immune system
to Shigella infection and its consequences on both bacterial survival and tissue alteration and repair are still not known in detail.
The purpose of this study is to analyze the relationships that exist
between invasiveness, inflammation, and immunogenicity in order to
define guidelines that would allow the construction of
Shigella vaccine candidates. With this aim we have evaluated the impact of both the route of infection and the intensity of the
innate immune response on the development of adaptive immune responses,
using the guinea pig model. Infection and vaccination were performed
using two routes of administration: the i.n. route to study the immune
potential and pathogenicity of shigellae in the respiratory tract and
the i.g. route to explore the effect of Shigella invasion
under conditions nearest to those that occur during natural infection.
To manipulate the degree of innate immune responses, strains of
Shigella with increasing degrees of attenuation were used:
the wild-type strain M90T and two strains with mutations in metabolic
functions necessary for bacterial growth in tissues, M90T
aroC, which is auxotrophic for p-aminobenzoic
acid (PABA), and M90T purE aroC, which is auxotrophic for
PABA and adenine. These three strains were analyzed for invasion
ability, induction of inflammation, and immunogenicity in guinea pigs.
Our strategy involved the i.n. or i.g. immunization of one set of
guinea pigs to evaluate the immunogenicity and the protective efficacy
of M90T, M90T aroC, and M90T purE aroC by using
the Sereny test and the i.n. or i.g. infection of another set of guinea
pigs to correlate the immune response to the actual degree of
pathogenicity and reactogenicity of the strains. These parameters were
evaluated by monitoring (i) the ability of mutant strains to colonize
different tissues, (ii) the persistence of bacteria within these
tissues, and (iii) the histopathological and immunohistochemical
analysis of infected tissues. Our results show that the ability to
induce a protective immune response depends on the immunization route, which indicates that both persistence of bacteria in infected tissues
and low reactogenicity are the major factors conferring protective immunity.
Bacterial strains and media.
Vaccine strains used in this
study are listed in Table 1. The
wild-type S. flexneri 5 strain M90T and Escherichia
coli 395.1 were routinely grown in Trypticase soy broth (Becton
Dickinson and Co., Cockeysville, Md.) or Trypticase soy broth agar
(TCSA) (Difco Laboratories, Detroit, Mich.). M90T
aroC::Tn10 and M90T
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.2.1072-1083.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Parameters Underlying Successful Protection with Live Attenuated
Mutants in Experimental Shigellosis
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
the wild-type M90T, an
aroC mutant, and a double purE aroC mutantfor
their pathogenicity, immunogenicity, and protective capacity.
Protection against keratoconjunctivitis, induced by wild-type M90T, was
used as the protection read out in guinea pigs that were inoculated
either intranasally or intragastrically. Following intranasal
immunization, the aroC mutant elicited weak nasal tissue
destruction compared to M90T and achieved protection correlated with
high levels of local anti-lipopolysaccharide immunoglobulin A (IgA),
whereas the purE aroC double mutant, which also elicited weak tissue destruction, was not protective and elicited a low IgA
response. Conversely, following intragastric immunization, only the
M90T purE aroC double mutant elicited protection compared to both the aroC mutant and the wild-type strain. This
mutant caused mild inflammatory destruction, particularly at the level of Peyer's patches, but it persisted much longer within the tissues. This could represent an essential parameter of the protective response
that, in this case, did not clearly correlate with high anti-lipopolysaccharide IgA titers.
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
(IL-1), a cytokine that elicits early inflammation
(35) from the dying macrophages (57). Immigration of polymorphonuclear cells (PMNs), recruited to the site of
infection, disrupts intercellular junctions between epithelial cells
and thereby facilitates bacterial access to the basolateral side of the
epithelium where bacteria can efficiently invade (29, 36).
This invasion eventually results in extensive inflammation and tissue
destruction of the villous epithelium adjacent to lymphoid follicles
(35, 43).
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
purE
aroC::Tn10 mutants were also cultured in
brain heart infusion (Bacto BHI; Difco). TCSA containing 100 mg of
Congo red dye per liter was used to select invasive clones of
Shigella spp. (28). When necessary,
tetracycline was added at a concentration of 10 µg/ml.
TABLE 1.
Vaccine strains used and relevant characteristics
Animals. Female Hartley guinea pigs weighing approximately 400 g were used for infection and immunization experiments. The animals were housed in individual cages.
Immunizations.
Guinea pigs were anesthesized with 20 mg of
ketamine per liter (Imalgène 1000; Rhone Mérieux, Lyon,
France) and immunized i.n. or i.g. with 109 microorganisms
harvested from overnight-growth plates. A total of 10 animals were
immunized for each strain (M90T, M90T
aroC::Tn10, M90T purE
aroC::Tn10, and E. coli 395.1).
The immunization schemes are shown in Fig.
1A and B.
|
(i)i.g. immunization.
Approximately 0.5 ml of bacterial cell
suspension was delivered into the stomach of a guinea pig through a
1-mm-diameter polyethylene feeding tube inserted into the
esophagus, immediately after administration by the same route of about
0.5 ml of 1.4% sodium bicarbonate in order to buffer gastric acidity.
Animals were immunized twice (day 0 and day 14). At days 0 and 32, sera
were collected from a foot vein. At days 0 and 21, samples of saliva
were recovered as follows: saliva was collected with a wick tampon
(Polyfiltronics Group Inc., Rockland, Mass.) left in the mouth for 3 min for full absorption. The wicks were then soaked in ice, weighed,
dipped in a 0.5-ml solution of phosphate-buffered saline (PBS)
containing 5% milk and protease inhibitors (1 mM phenylmethylsulfonyl
fluoride, 1 mM EDTA, and 0.5 µg of leupeptin per ml, all products of
Sigma Chemical Co., St. Louis, Mo.) (4). Subsequently, the
samples were vortexed and centrifuged for 2 min at 12,700 × g. Finally, the liquid phase was collected and stored at 
80°C.
(ii) i.n. immunization. Before immunization, animals were treated as described above; then a suspension of 109 bacteria in 0.1 ml was applied dropwise to the nares (0.05 ml for each nare). At days 0 and 28, sera were collected from a foot vein, whereas at days 0 and 21, samples of saliva were removed as specified above.
(iii) Intranconjunctival challenge. At days 32 and 28 for i.g. and i.n. administration, respectively, guinea pigs were challenged with 0.01 ml of an M90T suspension containing 109 bacteria. The suspension was deposited into the conjunctival sac of one eye using a dropper, and lids were slightly massaged to ensure that the inoculum was distributed over the entire eye. Following challenge with M90T, the animals were inspected daily for 7 days for the development of keratoconjunctivitis. The degree of keratoconjunctivitis was rated on the basis of time of development, severity, and (when possible) rate of clearance of the symptoms, using the following scheme: 0, no disease; 1, mild conjunctivitis; 2, keratoconjunctivitis with no purulence; and 3, fully developed keratoconjunctivitis with purulence (11). The percentage of protection was defined as follows: full protection, percentage of eyes with rating of 0; partial protection, percentage of eyes with rating of 1.
Infections.
Nine guinea pigs were infected i.n. or i.g.
using each strain of bacteria (M90T, M90T
aroC::Tn10, and M90T purE
aroC::Tn10). One untreated animal was
sacrificed, and its relevant tissues were used as a control.
(i) i.g. infection. Animals were infected i.g. with a suspension of 109 bacteria following the procedure described for i.g. immunization. At days 1, 3, and 7, three animals were sacrificed for each bacterial strain. Samples of liver and PPs were removed and prepared for both histopathological analysis and counts of viable bacteria. Briefly, relevant intestinal segments were dissected longitudinally, opened on their mesenteric side, and extensively washed with PBS. Four to seven PPs for each animal were punched off the tissue by using a 4-mm-diameter skin biopsy punch (Stiefel, Nanterre, France). Most of the overlying mucus was peeled off by direct contact with absorbing paper, followed by several washings with PBS. The liver was removed, weighed, and cut, and the sections were kept for further investigation. For histopathological analysis, PPs and liver samples were fixed in 4% formalin, whereas for bacterial counts, saline buffer was added to samples, and they were immediately stored in ice until further manipulation.
(ii) i.n. infection. At days 1, 3, and 7, three animals were sacrificed for each bacterial strain. Nasal mucosa or alternatively the nasal parts of the head in addition to the parotid glands and lungs were removed for both histopathological analysis and bacterial counts. Briefly, the nasal section was cut off along the line under the eyes, and the tip of the nose was removed after stripping the skin from the head. For bacterial counts, nasal mucosa was removed from the nasal cavities. For histopathological analysis the nasal section was stored in a solution of 4% formalin and 5% trichloroacetic acid. Parotid glands were removed by excision of the skin in the posterolateral section of each ear, and the lungs were removed from the thoracic cavity. For histopathological analysis, parotid glands and lungs were fixed in 4% formalin, whereas for bacterial counts saline buffer was added, and the samples were immediately stored in ice.
Bacterial counts in tissue samples. Tissue samples in ice-cold 0.9% NaCl (10 ml for lungs, 5 ml for nasal mucosa, parotids, and lungs, and 1 ml for each PP) were ground with an Ultraturrax apparatus (Janke and Kunkel, GmbH and Co., Staufen, Germany). Serial dilutions of the resulting solutions were plated on TCSA with or without tetracycline added and were incubated overnight at 37°C. Bacterial counts were normalized to the dilution factor and to the weight of the sample.
Histopathological analysis. After treatment with formalin, samples were dehydrated, embedded in paraffin, and sectioned in 5-µm-thick slices at various levels. Cuts were stained with hematoxylin-eosin or immunostained for observation. Damage to the architecture of the intestinal villi was evaluated by the index of intestinal atrophy, which involved measurement of the length of a villus divided by its width (L/W ratio). About 80 villi were analyzed, their length and width were recorded, and the L/W ratio was calculated. For the guinea pig control, the mean L/W ratio was 5.59.
Immunocytochemistry was performed as follows: the sections were deparaffinated and rehydrated, and endogenous peroxidases were blocked by 0.3% hydrogen peroxide in methanol. Bacterial lipopolysaccharide (LPS) was labeled using a biotinylated primary mouse monoclonal antibody (immunoglobulin G3 [IgG3], kappa chain) directed against the S. flexneri serotype 5 somatic antigen at a concentration of 5 µg/ml (37, 44). The preparations were incubated overnight at 4°C. The reaction was amplified by using a Vectastain ABC kit (Vector Laboratories, Inc., Burlingame, Calif.). Staining was obtained by incubation with the substrate chromogen (DAB) solution (3-3' diaminobenzidine tetrahydrochloride-H2O2 [Vector Laboratories, Inc.]). Counterstaining was obtained with Harris hematoxylin (Merck & Co., Rahway, N.J.). Final mounting was done on glycerol gel (Dako Corp., Carpinteria, Calif.).Serum and saliva analysis. An enzyme-linked immunosorbent assay (ELISA) was used to quantitate serum and salivary IgG and IgA against LPS.
A solution containing 10 µl of S. flexneri 5 purified LPS per ml of coating buffer (20 mM Na2CO3 [pH 9.6]) was used to coat 96-well microtiter plates (Immunoplates F96, Maxi Sorp; Nunc, Roskilde, Denmark) (100 µl per well) overnight at room temperature. The plates were washed with PBS-0.05% Tween 20, covered with a filler solution (1% bovine serum albumin in washing buffer), and incubated at room temperature for 1 h. The solution was aspirated, and the plates were washed with washing buffer. Guinea pig sera or saliva, serially diluted in filler solution, was added to the wells and incubated 1 h at 37°C. After this time and following washes with washing buffer, the plates were treated separately for the dosage of IgA or IgG. For anti-LPS IgA, the plates were incubated with a sheep primary antibody specific for guinea pig IgA (Bethyl Lab. Inc., Montgomery, Tex.), for 1 h at 37°C at a concentration of 1:1,000. After washing, a horseradish peroxidase (HRP)-conjugated donkey secondary-antibody anti-sheep IgG (heavy and light chains) (Bethyl Lab. Inc.) was added at a dilution of 1:5,000 and left 1 h at 37°C. Total IgA was evaluated as follows. First, a rabbit anti-guinea pig IgA (
chain) (Bethyl Lab. Inc.) was used at a concentration of 1:2,000
to coat the wells; then different dilutions of saliva were added and
IgA was quantitated with a sheep primary antibody anti-guinea pig IgA
(1:1,000 concentration). The HRP donkey anti-sheep IgG (heavy and light
chains) (1:5,000) (Bethyl Lab. Inc.) was used again in the revelation step.
For anti-LPS IgG, an HRP-conjugated sheep primary antibody against
guinea pig IgG (heavy and light chains) (Bethyl Lab. Inc.) was used at
a dilution of 1:10,000.
After these treatments ELISA plates were washed again and developed
with O-phenylenediamine (Sigma Chemical Co.) (0.3 mg/ml in
citrate buffer [pH 5.6]) and H2O2 (0.03%).
The reaction was blocked with H2SO4 (4 N), and
the absorbance was read at 490 nm in an ELISA reader (model MR 4000;
Dynatech Laboratories, Inc., Alexandria, Va.). The titers were defined
as the reciprocal of the last dilution having an optical density at 490 nm of 0.1 or more.
Statistical analysis. The attack rates for keratoconjunctivitis in vaccinated guinea pigs and controls following conjunctival sac challenge were compared by Fisher's exact test. An unpaired Student's t test was used to compare the mean value of CFU of bacteria recovered from infected tissues and the significance of the differences between the two immunization routes. The Mann-Whitney U test was performed to compare the mean titers of antibody elicited by the vaccine strains. The values were considered statistically significant for P < 0.05, whereas values of 0.05 < P < 0.09 were considered to be of borderline significance.
| |
RESULTS |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
Immunizations. Guinea pigs were immunized with S. flexneri 5 wild-type strain M90T, the auxotrophic mutants M90T aroC and M90T purE aroC, and E. coli strain 395.1, following the protocols described in Materials and Methods.
M90T aroC is an attenuated mutant in which auxotrophy for aromatic amino acids results in a negative Sereny test (3). In the plaque assay, which is an in vitro test that measures the ability of virulent shigellae to form areas of necrosis on a confluent HeLa cell monolayer, M90T aroC induces a cytopathic effect that is far weaker than that of the wild-type strain. Its intracellular generation time is longer than that of M90T (119 min versus 75 min) (3). M90T purE aroC, which harbors the adenine auxotrophy mutation (purE) in addition to the aroC mutation, is severely attenuated. It was found to be negative in the plaque assay and dramatically retarded in intracellular multiplication (intracellular generation time, 302 min), and it did not elicit a positive Sereny test (3). Although thepurE mutant was only weakly attenuated (3), the combination of this mutation with either the
aroC or aroD deletion further impaired the
virulence of these strains (3). E. coli 395.1 was used as a negative control in all immunization trials. Animals were
immunized following the schedule shown in Fig. 1. The Sereny test was
used to evaluate the protective efficacy and immunogenicity of the
vaccine candidates.
Normally, from 96 h postchallenge onwards, the severity of
symptoms decreased up to complete clearance. Therefore, only data relative to this period are shown. Results are summarized in Table 2.
|
Antibody response against M90T somatic antigen.
Immunogenicity
of the vaccine candidates was measured by determining the levels of
serum IgG and saliva IgA directed against S. flexneri 5 LPS.
All guinea pigs showed null antibody titers against S. flexneri before vaccination (data not shown). Approximately 2 weeks after the second immunization (at days 32 and 28 for i.g. and
i.n. immunization, respectively), animals were bled and the serum IgG
response against LPS was evaluated by ELISA. At day 21 postinfection
(p.i.), saliva was collected from animals, and anti-LPS IgA levels were
measured. Results shown in Fig. 2 and Table 3 demonstrate significant
differences in the levels of antibodies elicited by the two different
immunization routes in that higher levels of both IgG and IgA were
observed in animals vaccinated i.n. than in those vaccinated i.g.
(P = 0.0034 for IgG i.n. versus IgG i.g., and
P < 0.0001 for IgA i.n. versus IgA i.g.). At day 21, tears were also collected, and anti-LPS IgA levels in the tears were
measured. The results obtained were comparable to those observed in
saliva (data not shown).
|
|
Infections. The results obtained in immunization trials indicated that the vaccine strains demonstrated different capabilities for inducing protective immune responses depending on the immunization route. This finding suggested that the bacterial strains behaved differently in different host tissues. We reasoned that the probability of inducing an adaptive immune response relied on various factors including the ability of bacteria to colonize the host, to persist within an infected tissue, and to induce, to various degrees, an inflammatory response. To address these major points, M90T, M90T aroC, and M90T purE aroC were used to infect another pool of guinea pigs, either i.n. or i.g., and the ability of these strains to persist, disseminate, and induce an inflammatory response was then evaluated. Our aim was to compare the behavior of these strains in the tissues they infected in an attempt to detect an association between a specific bacterial trait in the host and the capacity to induce a protective immune response.
Two sets of guinea pigs were infected and sacrificed at different times p.i. Three animals for each strain in both infection protocols were sacrificed on days 1, 3, and 7, respectively. To measure the extent of bacterial dissemination in the host, several organs and tissues were processed. Briefly, nasal mucosa, parotids, and lungs were processed for animals infected i.n., and PPs and liver were processed for those challenged i.g. The number of bacteria was evaluated, and immunohistopathological analysis was performed. This analysis allowed us to monitor three essential parameters: bacterial colonization, dissemination, and persistence. In the intranasally infected animals, all bacterial strains tested reached the lungs, where they persisted for at least 7 days and disseminated into the parotids, as shown in Fig. 3. Although the number of bacteria decreased from day 3, approximately 4 × 104 bacteria were isolated on day 7 from the lungs of animals infected with M90T. In the nasal mucosa the number of bacteria from animals infected with M90T dramatically decreased during the 7 days of observation, whereas in parotid glands the number of bacteria from all infected animals increased during the same period. M90T colonized the tissues more efficiently than the other strains, and bacterial counts from animals infected with M90T purE aroC were the lowest.
|
|
Histopathology and immunohistochemistry performed on intestinal tissues of animals infected intragastrically. Histopathological analysis was performed on tissue sections removed from the intestines of animals sacrificed at days 1, 3, and 7. The sections usually included PPs and the surrounding area containing villi.
To perform a quantitative evaluation of the damage induced by the presence of bacteria within the intestine, we measured the L/W ratio of the villi. Changes in this ratio are provoked by intestinal atrophy subsequent to Shigella infection. About 80 villi per strain per day p.i. were examined, their lengths and widths were recorded, and the ratio was calculated. Data obtained and statistical analysis are shown in Table 4.
|
|
|
Histopathology and immunohistochemistry performed on upper
respiratory tissues of animals infected intranasally.
Histopathological analysis was performed on tissue sections from the
nasal mucosa of animals sacrificed at days 1, 3, and 7. As shown in
Fig. 7A, after 1 day of infection, the
wild-type strain M90T was able to cause massive inflammation (mostly
PMNs) of the chorion with ulceration of the associated simple
epithelium (arrowhead), reflecting necrosis of the epithelial lining. A
massive efflux of PMNs was observed through the ulcerations, with
formation of purulent plaques in the nasal cavity. In similar
conditions, the M90T aroC mutant also caused epithelial
alteration with ulceration and efflux of PMNs (arrowhead), although the
inflammatory infiltrate in the chorion appeared weaker (Fig. 7C). It is
interesting, as shown in Fig. 7, that the inflammation and destruction
ceased at the transition between the simple epithelium concerned in the process and the stratified squamous epithelium, which was preserved (arrow), suggesting that bacterial invasion occurred only in simple epithelia. As shown in Fig. 7E, the M90T purE aroC double
mutant also caused epithelial lesions, although of much weaker
intensity, in both the chorion and epithelial lining. The arrowhead in
this panel points to a typical zone of inflammatory infiltrate of the epithelial lining without significant rupture of this lining.
|
| |
DISCUSSION |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
To elicit the signaling cascade that ultimately induces the protective immune response, Shigella vaccine candidates probably need to retain sufficient invasiveness to deliver the appropriate signals but also to avoid causing symptomatic lesions by being sufficiently stealthy. However, finding a fine balance between invasiveness, inflammation, and immunogenicity is a particularly difficult objective to achieve (40), since Shigella invasiveness is mainly associated with the ability of the bacteria to induce a strong inflammatory reaction at the site of infection. In this work, we have attempted to further define rational bases for live vaccine design by means of virulence attenuation. In particular, we have analyzed in vivo the correlations existing between major parameters such as the degree of invasiveness, intensity of the inflammatory response, immunogenicity, and protective capacity of a S. flexneri 5 wild-type strain and of two of its attenuated mutants, auxotrophic for PABA (aroC) and for PABA and adenine (aroC purE), in guinea pigs infected by either the i.g. or the i.n. route. Immunogenicity was evaluated by assessing the ability of these strains to protect guinea pigs vaccinated either i.n. or i.g. against Shigella intraconjunctival challenge. In this way, we attempted to address several questions. (i) How does the route of inoculation influence the quality of the immune response with regard to protection against a virulent challenge? (ii) What differences can be observed among the wild-type strain and its mutants with regard to interaction with nasal and intestinal tissues (i.e., their ability to colonize, persist, disseminate within the host, and elicit an inflammatory reaction)? (iii) Is there a link between the degree of invasiveness, the inflammatory potential of strains, and their capacity to induce protective immunogenicity?
The first two questions focus on the differences between the two immunization routes. Our results indicate that the immune responses elicited by vaccine candidates are strongly influenced by the immunization routes, with the i.n. route being more efficient than the i.g. route (i.n. versus i.g.: P = 0.0063). Protection generated by i.n. immunization is accompanied by high specific anti-LPS IgA titers in saliva and tears (not shown). Accordingly, M90T purE aroC, which elicited the highest titer of total salivary IgA, was less protective than M90T and M90T aroC in that it elicited the lowest levels of specific salivary anti-LPS IgA. This issue is consistent with previous studies that reported, in the i.n. model of guinea pig vaccination, that high titers of anti-LPS IgA (31, 32) were associated with protection (33). Moreover, in the guinea pig keratoconjunctivitis model, high levels of antigen-specific antigen-secreting cells occur in superficial ventral cervical lymph nodes and correlate with the vaccine protective efficacy (12). In the mouse pulmonary model of shigellosis, high levels of IgA-ASC and high mucosal anti-LPS IgA titers were detected following two i.n. immunizations with wild-type S. flexneri 2a (49). Specifically, a monoclonal IgA directed against a serotype-specific epitope of S. flexneri LPS was demonstrated to confer protective immunity (37). However, this rationale does not completely account for the results obtained in i.g. immunizations. In this case, M90T and M90T purE aroC were the only strains conferring protective immunity, with the significant difference that M90T was only partially protective, whereas M90T purE aroC was fully protective. It is intriguing that only animals immunized with these two strains exhibited observable levels of anti-LPS IgA in tears (not shown) and saliva. Nevertheless, these titers were significantly lower than those measured in i.n. immunizations (P < 0.0001). The question of whether a low level of anti-LPS IgA alone supports the protection generated by the i.g. delivered M90T purE aroC and M90T remains unsolved.
Consistent with other studies (53) that focused on the
differences between the immune responses following either i.g. or i.n.
antigen administration, higher titers of serum anti-LPS IgG were found
in guinea pigs vaccinated i.n. than in those immunized i.g. However, it
has been shown that in the murine pulmonary model of shigellosis there
is no correlation between high anti-LPS IgG and protection
(25). In our study, under the i.g. regimen, only M90T and
M90T purE aroC stimulated significant levels of anti-LPS IgG, perhaps suggesting that these antibodies influence protection. In
humans, a significant correlation between anti-LPS IgG and resistance
to shigellosis was observed (5, 6), and
Shigella-LPS conjugates (composed of the O-specific
polysaccharides conjugated to a carrier protein) are protective and
induce high levels of anti-LPS IgG (7). Briefly, in the
model of i.n. vaccinated guinea pigs, protective immunity appears to be
correlated essentially with high levels of anti-LPS IgA, whereas in
animals vaccinated i.g., protection seems to be a multifactorial
process in which both anti-LPS IgA and IgG may contribute to the
response. These findings also suggest a possible role for cell-mediated
immune mechanisms in protective immunity following i.g. vaccination. In
fact, several studies implicate cell-mediated immunity as an essential
defense mechanism against shigellosis on the basis of results obtained
in animal models (49) and in human natural infections
(16, 17). A high production of both IL-10 and gamma interferon (IFN-
) from peripheral blood mononuclear cells of volunteers experimentally infected with Shigella spp. was
reported (39) to be accompanied by poor proliferative
response to all Shigella antigens accounted for by the
synergic effects of IL-10, IFN-, and transforming growth factor in decreasing IL-2 and IL-15 production. We hypothesize that this
pattern of cytokine induction and repression might be reversed in i.g.
immunization with the M90T purE aroC mutant, which, being
sufficiently stealthy, is able to persist longer in infected tissues.
Therefore, T-cell proliferation might occur, thus further potentiating
the immune response. Consistent with this hypothesis, a stronger CD45
response was observed at day 7 p.i. in T-cell areas of PPs of
animals infected with M90T purE aroC than in those infected
with M90T (data not shown).
In recent years, a certain number of Shigella attenuated strains have been constructed and evaluated as vaccine candidates (8, 23). These strains could be roughly classified into two groups: (i) mutants in which genes governing one or two main steps of the metabolism were inactivated (e.g., thyA, aroD, and aroA aroD) (1, 24, 50) and (ii) mutants harboring the icsA deletion in addition to one of the above-mentioned gene inactivations (2, 10, 21, 32, 34, 43, 54). The rationale underlying these constructions is that strains belonging to the first group are impaired in intracellular tissue replication, whereas the mutants in icsA are impaired also in intercellular dissemination. In the colonic and rectal mucosa of experimentally infected animals (43), inactivation of icsA restricts S. flexneri invasion to the epithelial cells overlying the lymphoid structures, strongly reducing bacterial colonization. The mutants used in this study are expected to disseminate into the infected tissues because they do not carry the icsA deletion. Their attenuation is based exclusively on a metabolic defect that reduces their intracellular multiplication, as previously shown in the tissue culture invasion assay (3). Following i.g. administration, M90T purE aroC was not recovered from PPs at day 1 p.i., but the number of bacteria progressively increased during the 7-day infection period. M90T bacterial counts showed opposite kinetics. Tissue lesions and inflammation were seldom seen with M90T purE aroC. By contrast, extensive alteration of the epithelial lining was seen in animals infected with M90T and M90T aroC, consistent with previous results obtained with M90T-infected ligated ileal loops in rabbits (44). At day 1 p.i., M90T was observed to be associated with the areas of intense destruction. Consequently, bacteria were rarely observed within the infected tissues after this point in time. At day 1 p.i., M90T purE aroC was located within the tips of villi and, at day 7 p.i., to a greater extent near the crypts. This latter observation indicates that this mutant is able to move within the epithelial layer and to reach areas far from the sites of entry. It was reported that in PPs, the number of dendritic cells (DCs) increases during infections at the sites of bacterial entry (19, 48). It could be hypothesized that M90T purE aroC may enter DCs in PPs and, through these cells, may reach the deeper layers of the intestinal epithelium. In fact, DCs were recently proposed as a vector for viable salmonellae or for Salmonella material during the course of salmonellosis (27). This tight interaction between salmonellae and DCs results in cytokine production and an increase in Salmonella dissemination. In support of this idea, M90T and M90T purE aroC were also isolated from liver tissue at days 1 and 3 and day 7, respectively, thus indicating that bacteria pass into the portal blood stream. Accordingly, S. flexneri 2a was also found to enter the blood stream in a rabbit model of shigellosis (9).
In i.n. infections, a great number of bacteria were isolated from
infected tissues, and all strains persisted longer than 1 week and
disseminated within the nose-associated organs, including the parotid
glands. Broad damage characterized by abscesses showing PMN
infiltrations was observed within the ciliated epithelium in the nasal
tract, which appears to be the primary site of bacterial entry.
Intensity of the lesions was inversely correlated with the attenuation
of the strain. The numbers of both bacteria cultured from and bacteria
detectable within these infected tissues were consistent with the
alterations produced. Therefore, at day 7 p.i. higher numbers of both
M90T and M90T aroC were found in all of the tissues examined
when compared to M90T purE aroC. As also reported for the
mouse model of shigellosis, the guinea pig nasal-infection model is
mainly characterized by the development of an intense inflammatory
reaction in the lungs with a leukocytic exudate that accumulates in
bronchi (data not shown). In a study by Van de Verg et al., challenging
of mice within injected S. flexneri 2a (49) led
to a prolonged increase in the proportion of monocytes or macrophages
in the lungs. Pulmonary IFN- levels were elevated, but only at
earlier time points of infection, and these levels then rapidly
decreased. Therefore, this early IFN- response could enhance
the microbicidal activity of infiltrating macrophages at
this time (49). Moreover, in humans, the frequency of
IFN- mRNA-expressing cells is significantly reduced during the acute stage of shigellosis compared to that observed during the
convalescent stage (38, 52). In guinea pigs infected
with all strains used in this study, the number of bacteria recovered
from lungs also decreased after 3 days p.i. However, after 7 days of
infection, this number did not change. This finding may indicate that,
as in humans and mice, the production of IFN-, responsible for the first clearance of bacteria, might be reduced in the acute stage of
infection, thus allowing maintenance of shigellae within the lungs.
On the basis of the results obtained following the two routes of infections, it can be concluded that, in our model, bacterial persistence within the infected tissues is a prerequisite for establishment of protective immunity. This might partially explain the success of i.n. immunization compared to the i.g. regimen. After i.g. administration, M90T purE aroC, although more attenuated, was able to persist longer in the tissues and was the only strain able to confer protective immunity. On the other hand, after i.n. administration, all strains persisted for extended periods within the tissues analyzed but to different extents. In these tissues, M90T purE aroC was more easily cleared, thus resulting in less protective immunity compared to that induced by M90T aroC and M90T.
This study highlights the need to investigate further the mechanisms that mediate the transition from the innate immune response to the adaptive immune response and, consequently, to develop better experimental animal models that more closely mimic the naturally occurring disease.
| |
ACKNOWLEDGMENTS |
|---|
We thank Michel Huerre and Nicole Wuscher for histopathological procedures, Daniele Remotti and Mariateresa Taffuri for advice in microscopical analysis, Armelle Phalipon for providing us with the anti-S. flexneri 5 LPS antibody and for helpful discussions, and Dana Philpott for careful reading of the manuscript and suggestions.
This work was supported in part by grants from the World Health Organization (V27/181/79) and from the European Union (QLK2-1999-00938).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Dipartimento di Biologia Cellulare e dello Sviluppo, Sezione di Scienze Microbiologiche, Università `La Sapienza,' Via dei Sardi 70, 00185 Rome, Italy. Phone: 3906 49917579. Fax: 3906 49917594. E-mail: bernardini{at}axcasp.caspur.it.
Editor: J. D. Clements
| |
REFERENCES |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
| 1. | Ahmed, Z. U., R. S. Mahfuzur, and D. A. Sack. 1990. Protection of adult rabbits and monkeys against shigellosis by oral immunization with a thymine-requiring and temperature-sensitive mutant of Shigella flexneri Y. Vaccine 8:153-158[CrossRef][Medline]. |
| 2. |
Bernardini, M. L.,
J. Mounier,
H. d'Hauteville,
M. Coquis-Rondon, and P. J. Sansonetti.
1989.
Identification of icsA, a plasmid locus of Shigella flexneri that governs intra- and intercellular spread through interaction with F-actin.
Proc. Natl. Acad. Sci. USA
86:3867-3871 |
| 3. |
Cersini, A.,
A. M. Salvia, and M. L. Bernardini.
1998.
Intracellular multiplication and virulence of Shigella flexneri auxotrophic mutants.
Infect. Immun.
66:549-557 |
| 4. |
Clark, B. D.,
I. Bedrosian,
R. Schindler,
F. Cominelli,
J. G. Cannon,
A. R. Shaw, and C. A. Dinarello.
1991.
Detection of interleukin 1 alpha and 1 beta in rabbit tissues during endotoxemia using sensitive radioimmunoassays.
J. Appl. Physiol.
71:2412-2418 |
| 5. | Cohen, D., M. S. Green, C. Block, T. Rouach, and L. Ofek. 1988. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J. Infect. Dis. 157:1068-1071[Medline]. |
| 6. |
Cohen, D.,
M. S. Green,
C. Block,
R. Slepon, and L. Ofek.
1991.
A prospective study on the association between serum antibodies to lipopolysaccharide and attack rate of shigellosis.
J. Clin. Microbiol.
29:386-389 |
| 7. | Cohen, D., S. Ashkenazi, M. Green, Y. Lerman, R. Slepon, G. Robin, N. Orr, D. N. Taylor, J. C. Sadoff, C. Chu, J. Shiloach, R. Schneerson, and J. B. Robbins. 1996. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect. Immun. 64:4074-4077[Abstract]. |
| 8. |
Coster, T. S.,
C. W. Hoge,
L. L. Van De Verg,
A. B. Hartman,
E. V. Oaks,
M. M. Venkatesan,
D. Cohen,
G. Robin,
A. Fontaine-Thompson,
P. J. Sansonetti, and T. L. Hale.
1999.
Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.
Infect. Immun.
67:3437-3443 |
| 9. | Etherridge, M. E., A. T. M. Shamsul Hoque, and D. A. Sack. 1996. Pathologic study of a rabbit model for shigellosis. Lab. Anim. Sci. 46:61-66[Medline]. |
| 10. | Fontaine, A., J. Arondel, and P. J. Sansonetti. 1990. Construction and evaluation of live attenuated vaccine strains of Shigella flexneri and Shigella dysenteriae. Res. Microbiol. 141:907-912[Medline]. |
| 11. |
Hartman, A. B.,
C. Powell,
C. L. Schultz,
E. V. Oaks, and K. H. Eckels.
1991.
Small animal model to measure efficacy and immunogenicity of Shigella vaccine strains.
Infect. Immun.
59:4075-4083 |
| 12. |
Hartman, A. B.,
L. L. Van De Verg,
H. H. Collins,
J., D. B. Tang,
N. O. Bendiuk,
D. N. Taylor, and C. J. Powell.
1994.
Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.
Infect. Immun.
62:412-420 |
| 13. |
Hartman, A. B., and M. M. Venkatesan.
1998.
Construction of a stable attenuated Shigella sonnei virG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model.
Infect. Immun.
66:4572-4576 |
| 14. |
Hilbi, H.,
Y. Chen,
K. Thirumalai, and A. Zychlinsky.
1997.
The interleukin 1-converting enzyme, caspase 1, is activated during Shigella flexneri-induced apoptosis in human monocyte-derived macrophages.
Infect. Immun.
65:5165-5170[Abstract].
|
| 15. | Huan, P. T., R. Taylor, A. A. Lindberg, and N. K. Verma. 1995. Immunogenicity of the Shigella flexneri serotype Y (SFL 124) vaccine strain expressing cloned glucosyl transferase gene of converting bacteriophage SfX. Microbiol. Immunol. 39:467-472[Medline]. |
| 16. | Islam, D., P. K. Bardhan, A. A. Lindberg, and B. Christensson. 1995. Shigella infection induces cellular activation of T and B cells and distinct species-related changes in peripheral blood lymphocyte subsets during the course of the disease. Infect. Immun. 63:2941[Abstract]. |
| 17. | Islam, D., B. Wretlind, A. A. Lindberg, and B. Christensson. 1996. Changes in the peripheral blood T-cell receptor VB repertoire in vivo and in vitro during shigellosis. Infect. Immun. 64:1391[Abstract]. |
| 18. | Kamell, A., B. A. D. Stocker, S. Katakura, F. P. Reinholt, and A. A. Lindberg. 1992. Live oral auxotrophic Shigella flexneri SFL124 vaccine with a deleted aroD gene: characterization and monkey protection studies. Vaccine 10:389-394[CrossRef][Medline]. |
| 19. |
Kelsall, B. L., and W. Strober.
1996.
Distinct populations of dendritic cells are present in the subepithelial dome and T cell regions of the murine Peyer's patch.
J. Exp. Med.
183:237-247 |
| 20. | Kotloff, K. L., J. P. Winickoff, B. Ivanoff, J. D. Clemens, D. L. Swerdlow, P. J. Sansonetti, G. K. Adak, and M. M. Levine. 1999. Global burden of Shigella infections: implications for vaccine development and implementation. Bull. W. H. O. 77:651-656[Medline]. |
| 21. |
Kotloff, K. L.,
F. R. Noriega,
T. Samandari,
M. B. Sztein,
G. A. Losonsky,
J. P. Nataro,
W. D. Picking,
E. M. Barry, and M. M. Levine.
2000.
Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.
Infect. Immun.
68:1034-1039 |
| 22. | Levine, M. M. 1982. Bacillary dysentery: mechanisms and treatment. Med. Clin. N. Am. 66:623[Medline]. |
| 23. | Levine, M. M., J. Galen, E. Barry, F. Noriega, C. Tacket, M. Sztein, S. Chatfield, G. Daugan, G. Losonsky, and K. Kotloff. 1997. Attenuated Salmonella typhi and Shigella as live oral vaccines and as live vectors. Behring Inst. Mitt. 98:120-123. |
| 24. | Lindberg, A. A., A. Kamell, B. A. D. Stocker, S. Katakura, H. Sweiha, and F. Reinholt. 1988. Development of an auxotrophic oral live Shigella flexneri vaccine. Vaccine 6:146-150[CrossRef][Medline]. |
| 25. | Mallett, C. P., L. L. Van De Verg, H. H. Collins, and T. L. Hale. 1993. Evaluation of Shigella vaccine safety and efficacy in an intranasal challenged mouse model. Vaccine 11:190-196[CrossRef][Medline]. |
| 26. | Mallett, C. P., T. L. Hale, R. W. Kaminski, T. Larsen, N. Orr, D. Cohen, and G. H. Lowell. 1995. Intranasal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection. Infect. Immun. 63:2382-2386[Abstract]. |
| 27. | Marriott, I., T. G. Hammond, E. K. Thomas, and L. B. Kenneth. 1999. Salmonella efficiently enter and survive within cultured CD11c+ dendritic cells initiating cytokine expression. Eur. J. Immunol. 29:1107-1115[CrossRef][Medline]. |
| 28. |
Maurelli, A. T.,
B. Blackmon, and R. Curtiss, III.
1984.
Temperature-dependent expression of virulence genes in Shigella species.
Infect. Immun.
43:195-201 |
| 29. |
Mounier, J.,
T. Vasselon,
R. Hellio,
M. Lesourd, and P. J. Sansonetti.
1992.
Shigella flexneri enters human colonic Caco-2 epithelial cells through the basolateral pole.
Infect. Immun.
60:237-248 |
| 30. |
Noriega, F. R.,
J. Y. Wang,
G. Losonsky,
D. R. Maneval,
D. M. Hone, and M. M. Levine.
1994.
Construction and characterization of attenuated aroA and icsA Shigella flexneri strain CVD 1203, a prototype live oral vaccine.
Infect. Immun.
62:5168-5172 |
| 31. |
Noriega, F. R.,
G. Losonsky,
J. Y. Wang,
S. B. Formal, and M. M. Levine.
1996.
Further characterization of aroA virG Shigella flexneri 2A strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli.
Infect. Immun.
64:23-27[Abstract].
|
| 32. |
Noriega, F. R.,
G. Losonsky,
C. Lauderbaugh,
F. M. Liao,
J. Y. Wang, and M. M. Levine.
1996.
Engineered guaB-A virG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine.
Infect. Immun.
64:3055-3061[Abstract].
|
| 33. |
Noriega, F. R.,
F. M. Liao,
D. R. Maneval,
S. Ren,
S. B. Formal, and M. M. Levine.
1999.
Strategy for cross-protection among Shigella flexneri serotypes.
Infect. Immun.
67:782-788 |
| 34. | Okada, N., C. Sasakawa, T. Tobe, K. A. Talukder, K. Komatsu, and M. Yoshikawa. 1991. Construction of a physical map of the chromosome of Shigella flexneri 2A and the direct assignment of nine virulence-associated loci identified by Tn5 insertions. Mol. Microbiol. 5:2171-2180[Medline]. |
| 35. |
Perdomo, J. J.,
J. M. Cavaillon,
M. Huerre,
H. Ohayon,
P. Gounon, and P. J. Sansonetti.
1994.
Acute inflammation causes epithelial invasion and mucosal destruction in experimental shigellosis.
J. Exp. Med.
180:1307-1319 |
| 36. | Perdomo, J. J., P. Gaunon, and P. J. Sansonetti. 1994. Polymorphonuclear leukocyte transmigration promotes invasion of colonic epithelial monolayer by Shigella flexneri. J. Clin. Invest. 93:633-643. |
| 37. |
Phalipon, A.,
M. Kaufmann,
P. Michetti,
J. M. Cavaillon,
M. Huerre,
P. J. Sansonetti, and J. P. Kraehembuhl.
1995.
Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis.
J. Exp. Med.
182:769-778 |
| 38. | Raqib, R., A. Gustafsson, J. Andersson, and M. Bakhiet. 1997. A systemic downregulation of gamma interferon production is associated with acute shigellosis. Infect. Immun. 65:5338-5341[Abstract]. |
| 39. |
Samandari, T.,
K. L. Kotloff,
G. A. Losonsky,
W. D. Picking,
P. J. Sansonetti,
M. M. Levine, and M. B. Sztein.
2000.
Production of IFN- and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain.
J. Immunol.
164:2221-2232 |
| 40. | Sansonetti, P. J. 1998. Pathogenesis of shigellosis: from molecular and cellular biology of epithelial cell invasion to tissue inflammation and vaccine development. Jpn. J. Med. Sci. Biol. 51(Suppl. 1):S69-S80. |
| 41. |
Sansonetti, P. J.,
D. J. Kopecko, and S. B. Formal.
1982.
Involvement of a plasmid in the invasive ability of Shigella flexneri.
Infect. Immun.
35:852-860 |
| 42. |
Sansonetti, P. J.,
T. L. Hale,
G. J. Dammin,
C. Kapfer,
H. H. Collins, Jr., and S. B. Formal.
1983.
Alterations in the pathogenicity of Escherichia coli K-12 after transfer of plasmid and chromosomal genes from Shigella flexneri.
Infect. Immun.
39:1392-1402 |
| 43. | Sansonetti, P. J., J. Arondel, A. Fontaine, H. d'Hauteville, and M. L. Bernardini. 1991. ompB (osmo-regulation) and icsA (cell to cell spread) mutants of Shigella flexneri: vaccine candidates and probes to study the pathogenesis of shigellosis. Vaccine 9:416-422[CrossRef][Medline]. |
| 44. | Sansonetti, P. J., J. Arondel, J. R. Cantey, M. C. Prevost, and M. Huerre. 1996. Infection of rabbit Peyer's patches by Shigella flexneri: effect of adhesive or invasive bacterial phenotypes on follicle-associated epithelium. Infect. Immun. 64:2752-2764[Abstract]. |
| 45. |
Sasakawa, C.,
K. Kamata,
T. Sakai,
S. Makino,
M. Yamada,
N. Okada, and M. Yoshikawa.
1988.
Virulence-associated genetic regions comprising 31 kilobases of the 230-kilobase plasmid in Shigella flexneri 2a.
J. Bacteriol.
170:2480-2484 |
| 46. | Sereny, B. 1957. Experimental keratoconjunctivitis shigellosa. Acta Microbiol. Acad. Sci. Hung. 4:367-376[Medline]. |
| 47. | Sereny, B. 1962. A new method for the measurement of protective potency of dysentery vaccines. Acta Microbiol. Acad. Sci. Hung. 9:55-60[Medline]. |
| 48. |
Sousa, C. R.,
S. Hieny,
T. Scharton-Kersten,
D. Jankovic,
H. Charest,
R. N. Germain, and A. Sher.
1997.
In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas.
J. Exp. Med.
186:1819-1829 |
| 49. | Van de Verg, L. L., C. P. Mallett, H. H. Collins, T. Larsen, C. Hammack, and T. L. Hale. 1995. Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection. Infect. Immun. 63:1947-1954[Abstract]. |
| 50. | Verma, N. K., and A. A. Lindberg. 1991. Construction of aromatic dependent Shigella flexneri 2a live vaccine candidate strains: deletion mutations in the aroA and the aroD genes. Vaccine 9:6-9[CrossRef][Medline]. |
| 51. |
Wassef, J. S.,
D. F. Keren, and J. L. Mailloux.
1989.
Role of M cells in initial antigen uptake and in ulcer formation in the rabbit intestinal loop model of shigellosis.
Infect. Immun.
57:858-863 |
| 52. |
Way, S. S.,
A. C. Borczuk,
R. Dominitz, and M. B. Goldberg.
1998.
An essential role for gamma interferon in innate resistance to Shigella flexneri infection.
Infect. Immun.
66:1342-1348 |
| 53. | Wu, H.-Y., E. B. Nikolova, K. W. Beagley, J. H. Eldrige, and M. W. Russell. 1997. Development of antibody-secreting cells and antigen-specific T cells in cervical lymph nodes after intranasal immunization. Infect. Immun. 65:227-235[Abstract]. |
| 54. | Yoshikawa, M., C. Sasakawa, N. Okada, M. Takasaka, M. Nakayama, Y. Yoshikawa, A. Kohno, H. Danbara, H. Nariuchi, H. Shimada, and M. Toriumi. 1995. Construction and evaluation of a virG thyA double mutant of Shigella flexneri 2a as candidate live-attenuated oral vaccine. Vaccine 13:1436-1440[CrossRef][Medline]. |
| 55. | Zychlinsky, A., M. C. Prevost, and P. J. Sansonetti. 1992. Shigella flexneri induces apoptosis in infected macrophages. Nature 358:167-169[CrossRef][Medline]. |
| 56. | Zychlinsky, A., B. Kenny, R. Menard, M. C. Prevost, I. B. Holland, and P. J. Sansonetti. 1994. IpaB mediates macrophage apoptosis induced by Shigella flexneri. Mol. Microbiol. 11:619-627[Medline]. |
| 57. | Zychlinsky, A., C. Fitting, J. M. Cavaillon, and P. J. Sansonetti. 1994. Interleukin 1 is released by murine macrophages during apoptosis induced by Shigella flexneri. J. Clin. Invest. 94:1328-1332. |
Infection and Immunity, February 2001, p. 1072-1083, Vol. 69, No. 2
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.2.1072-1083.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Shim, D.-H., Suzuki, T., Chang, S.-Y., Park, S.-M., Sansonetti, P. J., Sasakawa, C., Kweon, M.-N.
(2007). New Animal Model of Shigellosis in the Guinea Pig: Its Usefulness for Protective Efficacy Studies. J. Immunol.
178: 2476-2482
[Abstract] [Full Text] -
Suzuki, T., Yoshikawa, Y., Ashida, H., Iwai, H., Toyotome, T., Matsui, H., Sasakawa, C.
(2006). High Vaccine Efficacy against Shigellosis of Recombinant Noninvasive Shigella Mutant That Expresses Yersinia Invasin. J. Immunol.
177: 4709-4717
[Abstract] [Full Text] -
Singer, M., Sansonetti, P. J.
(2004). IL-8 Is a Key Chemokine Regulating Neutrophil Recruitment in a New Mouse Model of Shigella-Induced Colitis. J. Immunol.
173: 4197-4206
[Abstract] [Full Text] -
Cersini, A., Martino, M. C., Martini, I., Rossi, G., Bernardini, M. L.
(2003). Analysis of Virulence and Inflammatory Potential of Shigella flexneri Purine Biosynthesis Mutants. Infect. Immun.
71: 7002-7013
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»